We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.8B
AUM Growth
+$1.2B
Cap. Flow
+$591M
Cap. Flow %
8.68%
Top 10 Hldgs %
38.38%
Holding
154
New
24
Increased
52
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$204M
2
PRGO icon
Perrigo
PRGO
+$111M
3
ABBV icon
AbbVie
ABBV
+$99.2M
4
CELG
Celgene Corp
CELG
+$71.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$70.4M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$169M
2
ELV icon
Elevance Health
ELV
+$69M
3
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
+$56.2M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$53.1M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.58%
2 Financials 1.18%
3 Technology 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESRX
26
DELISTED
Express Scripts Holding Company
ESRX
$90.4M 1.33%
1,287,000
-496,000
-28% -$32.4M
CFN
27
DELISTED
CAREFUSION CORPORATION
CFN
$86.5M 1.27%
2,171,500
+968,200
+80% +$37.6M
AGN
28
DELISTED
Allergan Inc
AGN
$86.1M 1.27%
775,200
+478,200
+161% +$45.7M
XLRN
29
DELISTED
Acceleron Pharma
XLRN
$83.9M 1.23%
+2,117,648
New +$51.1M
AET
30
DELISTED
Aetna Inc
AET
$80.5M 1.18%
1,173,100
-379,900
-24% -$24.8M
ZBH icon
31
Zimmer Biomet
ZBH
$18.6B
$77.8M 1.14%
860,256
+813,906
+1,756% +$70.4M
MOH icon
32
Molina Healthcare
MOH
$10.5B
$71.7M 1.05%
2,063,100
+229,100
+12% +$7.72M
INFI
33
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$66.2M 0.97%
4,794,300
+201,700
+4% +$2.85M
UNH icon
34
UnitedHealth
UNH
$387B
$59.6M 0.88%
791,000
-538,000
-40% -$38.6M
EXAS
35
DELISTED
Exact Sciences
EXAS
$58.6M 0.86%
4,989,300
+309,000
+7% +$3.54M
AFFX
36
DELISTED
Affymetrix Inc
AFFX
$58.4M 0.86%
6,810,000
+162,000
+2% +$1.24M
EXEL icon
37
Exelixis
EXEL
$14.1B
$57.6M 0.85%
9,389,000
+645,000
+7% +$3.55M
JNJ icon
38
Johnson & Johnson
JNJ
$645B
$57.3M 0.84%
626,000
-27,000
-4% -$2.49M
MCK icon
39
McKesson
MCK
$106B
$57.3M 0.84%
355,000
+279,000
+367% +$42.9M
LAB icon
40
Standard BioTools
LAB
$322M
$55.4M 0.81%
1,446,008
+29,400
+2% +$866K
SYK icon
41
Stryker
SYK
$135B
$53.9M 0.79%
716,700
+650,700
+986% +$47.5M
STJ
42
DELISTED
St Jude Medical
STJ
$51.6M 0.76%
833,600
+713,600
+595% +$41.3M
HNT
43
DELISTED
HEALTH NET INC
HNT
$46.3M 0.68%
1,561,400
+291,800
+23% +$8.73M
QGENF
44
DELISTED
QIAGEN NV
QGENF
$45.9M 0.67%
+1,927,000
New +$45.9M
ELV icon
45
Elevance Health
ELV
$82.7B
$39.6M 0.58%
429,000
-777,000
-64% -$69M
PRTA icon
46
Prothena Corp
PRTA
$443M
$31.9M 0.47%
+1,202,000
New +$30.1M
CLDX icon
47
Celldex Therapeutics
CLDX
$2.81B
$31.7M 0.47%
+87,373
New +$33.7M
OSUR icon
48
OraSure Technologies
OSUR
$275M
$31.4M 0.46%
4,988,000
+127,900
+3% +$803K
ALXN
49
DELISTED
Alexion Pharmaceuticals
ALXN
$30.9M 0.45%
232,900
+17,000
+8% +$2.04M
BMY icon
50
CALL
Bristol-Myers Squibb
BMY
$130B
$29.2M 0.43%
550,000
+300,000
+120% +$15.3M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2013 Portfolio in Review

As of Q4 2013, OrbiMed held 154 positions worth $6.8B, up 21% from $5.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $591M of net new capital in Q4 2013, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was RELYPSA INC COM: 9,941,549 shares worth $249M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 84% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Merck, an estimated $169M trimmed.

  • OrbiMed's largest Q4 2013 buy was RELYPSA INC COM: 9,941,549 shares worth $249M.
  • OrbiMed added most to AbbVie in Q4 2013, an estimated $99.2M increase.
  • OrbiMed's biggest Q4 2013 reduction was Merck, cutting an estimated $169M.
  • OrbiMed fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $56.2M.
  • OrbiMed's ten largest holdings make up 38% of its $6.8B portfolio in Q4 2013.
  • OrbiMed opened 24 new positions and closed 34 in Q4 2013.
  • OrbiMed's portfolio value rose 21% quarter-over-quarter to $6.8B.

Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.